UB Paderborn / Katalog / Suche / in CDI

790-P: An Indirect Treatment Comparison of the Cardiovascular Protective Effect of Semaglutide vs. Liraglutide in Subjects with Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus

Diabetes therapy, 2017-04, Vol.8 (2), p.275-291

2017

Link zum Volltext

Verfügbarkeit prüfen

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.491-500

2023

Link zum Volltext

Verfügbarkeit prüfen

Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis

Diabetes therapy, 2021-05, Vol.12 (5), p.1325-1339

2021

Link zum Volltext

Verfügbarkeit prüfen

The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials

Diabetes research and clinical practice, 2021-05, Vol.175, p.108759-108759, Article 108759

2021

Link zum Volltext

Verfügbarkeit prüfen

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting

PharmacoEconomics, 2016-09, Vol.34 (9), p.953-966

2016

Link zum Volltext

Verfügbarkeit prüfen

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg

Diabetes, obesity & metabolism, 2021-11, Vol.23 (11), p.2513-2520

2021

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting

Diabetes therapy, 2018-10, Vol.9 (5), p.1919-1930

2018

Link zum Volltext

Verfügbarkeit prüfen

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes

Diabetes therapy, 2023-01, Vol.14 (1), p.123-137

2023

Link zum Volltext

Verfügbarkeit prüfen

Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment

Advances in therapy, 2022-09, Vol.39 (9), p.4114-4130

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

Journal of medical economics, 2020-01, Vol.23 (1), p.98-105

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

Advances in therapy, 2020-05, Vol.37 (5), p.2427-2441

2020

Link zum Volltext

Verfügbarkeit prüfen

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

Diabetes therapy, 2020-01, Vol.11 (1), p.259-277

2020

Link zum Volltext

Verfügbarkeit prüfen

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK

The European journal of health economics, 2023-08, Vol.24 (6), p.895-907

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting

PharmacoEconomics - open, 2022-05, Vol.6 (3), p.343-354

2022

Link zum Volltext

Verfügbarkeit prüfen

Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

Journal of medical economics, 2023, Vol.26 (1), p.1019-1031

2023

Link zum Volltext

Verfügbarkeit prüfen

Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey

Journal of medical economics, 2013-11, Vol.16 (11), p.1357-1365

2013

Link zum Volltext

Verfügbarkeit prüfen

Frequency of blood glucose testing among insulin-treated diabetes mellitus patients in the United Kingdom

Journal of medical economics, 2014-03, Vol.17 (3), p.167-175

2014

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia

Diabetes therapy, 2018-06, Vol.9 (3), p.1201-1216

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach

Diabetes, metabolic syndrome and obesity, 2018-01, Vol.11, p.217-226

2018

Link zum Volltext

Verfügbarkeit prüfen

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

Patient preference and adherence, 2013-01, Vol.7 (default), p.925-936

2013

Link zum Volltext

Verfügbarkeit prüfen

Flexible Insulin Dosing Improves Health-Related Quality of Life (HRQoL): A Time Trade-off Survey

Canadian journal of diabetes, 2013-10, Vol.37, p.S38-S39

2013

Link zum Volltext

Verfügbarkeit prüfen

The cost of needlestick injuries associated with insulin administration

British journal of community nursing, 2008-09, Vol.13 (9), p.413

2008

Link zum Volltext

Verfügbarkeit prüfen

Is the future for clinical trials internet-based? A cluster randomized clinical trial

Clinical trials (London, England), 2005-01, Vol.2 (1), p.72-79

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

790-P: An Indirect Treatment Comparison of the Cardiovascular Protective Effect of Semaglutide vs. Liraglutide in Subjects with Type 2 Diabetes

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11

Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis

The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes

Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment

Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting

Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey

Frequency of blood glucose testing among insulin-treated diabetes mellitus patients in the United Kingdom

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

Flexible Insulin Dosing Improves Health-Related Quality of Life (HRQoL): A Time Trade-off Survey

The cost of needlestick injuries associated with insulin administration

Is the future for clinical trials internet-based? A cluster randomized clinical trial

Suchergebnisse filtern